Stock Events

Stock Events

Alaunos Therapeutics 

€14.93
0
-€134.33-90% Monday 20:00

Statistics

Day High
1
Day Low
1
52W High
149.25
52W Low
1
Volume
430
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow WEK.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, Inc. has a strong presence in cell therapy for cancer, competing in the same space as Alaunos with its Yescarta and other cellular therapies.
Novartis
NVS
Mkt Cap279.67B
Novartis AG has been a pioneer in CAR-T cell therapy for cancer, competing in the broader market of advanced cancer therapies alongside Alaunos.
Pfizer
PFE
Mkt Cap149.77B
Pfizer Inc. has investments in cancer therapy, including CAR-T and potentially TCR-like therapies, making it a competitor in the oncology space.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. is heavily involved in cancer treatment through immunotherapy and could potentially expand into TCR therapies, competing with Alaunos.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb Company has a broad portfolio in oncology, including cell therapies, which could compete with Alaunos's TCR approaches.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its Janssen subsidiary, is investing in cancer therapies, including cell therapy, posing potential competition to Alaunos.

About

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Show more...
CEO
Mr. Holger Weis CPA
Employees
1
Country
United States
ISIN
US98973P3091

Listings

MU
DE
WEK.MU
XNAS
US
TCRT
BOATS
BOATS
TCRT.BOATS

0 Comments

Share your thoughts

FAQ

What is Alaunos Therapeutics stock price today?▼
The current price of WEK.MU is €14.93 EUR — it has decreased by -90% in the past 24 hours. Watch Alaunos Therapeutics stock price performance more closely on the chart.
What is Alaunos Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alaunos Therapeutics stocks are traded under the ticker WEK.MU.
Is Alaunos Therapeutics stock price growing?▼
WEK.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Alaunos Therapeutics has showed a +0% increase.
When is the next Alaunos Therapeutics earnings date?▼
Alaunos Therapeutics is going to release the next earnings report on May 13, 2026.
How many employees does Alaunos Therapeutics have?▼
As of May 06, 2026, the company has 1 employees.
In which sector is Alaunos Therapeutics located?▼
Alaunos Therapeutics operates in the Health & Wellness sector.
When did Alaunos Therapeutics complete a stock split?▼
Alaunos Therapeutics has not had any recent stock splits.
Where is Alaunos Therapeutics headquartered?▼
Alaunos Therapeutics is headquartered in Houston, United States.